Cargando…

Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?

Pancreatic ductal adenocarcinoma is characterized by its high morbidity, and curative drugs are still lacking. In addition to immunotherapy, other molecular targeted therapeutics, such as stroma depleting agents, have been evaluated, given the abundant desmoplastic stroma that is considered a protec...

Descripción completa

Detalles Bibliográficos
Autor principal: Delma, Mohamed Islam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657315/
https://www.ncbi.nlm.nih.gov/pubmed/33194476
http://dx.doi.org/10.7759/cureus.10909
_version_ 1783608478496980992
author Delma, Mohamed Islam
author_facet Delma, Mohamed Islam
author_sort Delma, Mohamed Islam
collection PubMed
description Pancreatic ductal adenocarcinoma is characterized by its high morbidity, and curative drugs are still lacking. In addition to immunotherapy, other molecular targeted therapeutics, such as stroma depleting agents, have been evaluated, given the abundant desmoplastic stroma that is considered a protective shield for tumor cells. However, the unexpected poor outcome has raised the debate on whether desmoplasia promotes or restrains tumor cell spread. After reviewing these key points in this paper, an approach taking advantage of desmoplasia and immune cells to besiege the tumoral sites will be proposed. Based on the available literature, the feasibility and potential limitations of this strategy will be discussed. 
format Online
Article
Text
id pubmed-7657315
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-76573152020-11-12 Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma? Delma, Mohamed Islam Cureus Internal Medicine Pancreatic ductal adenocarcinoma is characterized by its high morbidity, and curative drugs are still lacking. In addition to immunotherapy, other molecular targeted therapeutics, such as stroma depleting agents, have been evaluated, given the abundant desmoplastic stroma that is considered a protective shield for tumor cells. However, the unexpected poor outcome has raised the debate on whether desmoplasia promotes or restrains tumor cell spread. After reviewing these key points in this paper, an approach taking advantage of desmoplasia and immune cells to besiege the tumoral sites will be proposed. Based on the available literature, the feasibility and potential limitations of this strategy will be discussed.  Cureus 2020-10-12 /pmc/articles/PMC7657315/ /pubmed/33194476 http://dx.doi.org/10.7759/cureus.10909 Text en Copyright © 2020, Delma et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Delma, Mohamed Islam
Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
title Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
title_full Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
title_fullStr Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
title_full_unstemmed Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
title_short Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
title_sort besieging the tumoral sites: could it be an alternative therapeutic strategy in ductal pancreatic adenocarcinoma?
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657315/
https://www.ncbi.nlm.nih.gov/pubmed/33194476
http://dx.doi.org/10.7759/cureus.10909
work_keys_str_mv AT delmamohamedislam besiegingthetumoralsitescoulditbeanalternativetherapeuticstrategyinductalpancreaticadenocarcinoma